RIGEL EVP awarded 7,394 performance stock options
RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock. The option has an exercise price of $22.49 per share and an expiration date of January 29, 2035.
The award was originally granted on January 29, 2025 with a performance-based vesting condition, and it became fully vested on June 17, 2026 when the company determined that the performance metric had been met.
Insider Trade Summary
Grant/Award: 7,394 shares
Grant/Award
1 txn
Insider
Santos David A
Role
EVP, Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 7,394 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 7,394 contracts (Direct)
Footnotes (2)
- F1. The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met.
- F2. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met.
Key Figures
Option size: 7,394 shares
Exercise price: $22.49 per share
Expiration date: January 29, 2035
+1 more
4 metrics
Option size
7,394 shares
Underlying common stock in performance-based option
Exercise price
$22.49 per share
Closing price on Nasdaq on January 29, 2025
Expiration date
January 29, 2035
Option term end
Vesting date
June 17, 2026
Date performance metric determined met; option fully vested
Key Terms
performance-based condition, performance metric, Section 16, vesting
4 terms
performance-based condition financial
"The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares"
performance metric financial
"In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied."
Section 16 regulatory
"this grant was not reportable under Section 16 until the performance metric was satisfied."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
vesting financial
"The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did RIGEL (RIGL) report for David A. Santos?
RIGEL reported that EVP and Chief Commercial Officer David A. Santos received a performance-based stock option for 7,394 shares. The option became fully vested on June 17, 2026 once the company determined the required performance metric had been satisfied.
What is the exercise price of David A. Santos’s RIGEL stock option?
The exercise price of David A. Santos’s stock option is $22.49 per share. This price equals the closing price of RIGEL’s common stock on Nasdaq on January 29, 2025, the original grant date of the performance-based award.
When does David A. Santos’s RIGEL performance-based option expire?
David A. Santos’s performance-based stock option expires on January 29, 2035. This provides a long exercise window following its full vesting on June 17, 2026, when RIGEL determined that the specified performance metric had been achieved.
Why was David A. Santos’s RIGEL option reported now under Section 16?
The option was reported once its performance condition was met on June 17, 2026. Because vesting depended on a performance metric, the grant was not reportable under Section 16 until RIGEL determined that metric had been satisfied, triggering full vesting.
Is David A. Santos’s RIGEL transaction an open-market stock purchase or sale?
No, the transaction is a grant of a performance-based stock option, not an open-market trade. It represents equity compensation awarded by RIGEL, with 7,394 underlying shares at a $22.49 exercise price and full vesting once the performance metric was met.
AI-generated analysis. How Rhea-AI works. Not financial advice.
